Guangdong Biolight Meditech Hits Day Low of CNY 13.66 Amid Price Pressure

Guangdong Biolight Meditech Co., Ltd. experienced a significant decline today, with the stock dropping by 9.28% and reaching an intraday low of CNY 13.66. This performance stands in stark contrast to the China Shanghai Composite, which saw a modest gain of 0.5% on the same day. Over the past week, Guangdong Biolight has faced a steep decline of 21.88%, while its monthly performance shows a decrease of 17.57%. Despite a notable annual increase of 76.1%, the stock's long-term trajectory raises concerns, particularly with a five-year performance decline of 27.62% and a ten-year drop of 53.66%. Financial metrics indicate challenges, with net sales declining at an annual rate of 5.01% and operating profit plummeting by 172.31% over the last five years. The company's net profit for the first half of the year was reported at CNY -68.48 million, reflecting a growth rate of -114.31%. Additionally, the inventory turnover ratio stands at a low 3.12 times, highlighting operational inefficiencies. With a market capitalization of CNY 3,289 million, Guangdong Biolight remains a small-cap player in the pharmaceuticals and biotechnology sector.